Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics (Nasdaq: VKTX) announced a proposed underwritten public offering of its common stock on
Viking Therapeutics (VKTX) has commenced a Phase 1 clinical study of VK2735, an oral formulation of its dual GLP-1 and GIP receptor agonist. This study follows a recently completed Phase 1 trial of a subcutaneous version of VK2735, which showed promising results, including a body weight reduction of up to 7.8% in participants. The Phase 1 trial of the oral formulation aims to assess safety, tolerability, and pharmacokinetics over 28 days in healthy adults. Results from this study are expected in the second half of 2023, and Viking plans to advance to a Phase 2 trial for the subcutaneous formulation focused on obesity treatment.
Viking Therapeutics (NASDAQ: VKTX) announced promising results from its Phase 1 clinical trial for VK2735, a dual GLP-1/GIP receptor agonist aimed at treating metabolic disorders. The trial demonstrated a placebo-adjusted mean weight loss of 6.0% and a total weight loss of 7.8% from baseline over 28 days. VK2735 was found to be safe and well-tolerated, with the majority of adverse events being mild to moderate. A Phase 2 trial targeting obesity is slated for mid-2023, with further dose escalation planned based on these results.
Viking Therapeutics (NASDAQ: VKTX) announced its participation in two investor conferences on March 7, 2023. Brian Lian, Ph.D., CEO, will engage in a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, at 2:30 p.m. PT on March 13. Additionally, Dr. Lian will present at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023, at 7:40 a.m. PT on March 14. A live webcast of the Oppenheimer presentation will be available on the Viking website. Viking focuses on developing therapies for metabolic and endocrine disorders, with three compounds in clinical trials, including VK2809 for NASH and VK2735 for metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) announced its financial results for Q4 2022, reporting a net loss of $19.6 million or $0.26 per share, up from $12.4 million or $0.16 per share in Q4 2021. For the full year, its net loss was $68.9 million, compared to $55.0 million in 2021. The company is advancing its clinical pipeline, with enrollment completed in the Phase 2b VOYAGE trial for VK2809 targeting NASH and fibrosis, data expected in Q2 2023. Viking holds $155 million in cash, providing a solid financial foundation to pursue its clinical milestones and upcoming data releases for various programs, including VK2735 and VK0214.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced that CEO Brian Lian, Ph.D., will present at the SVB Securities Global Biopharma Conference from February 13-16, 2023. The presentation is scheduled for February 15 at 2:20 p.m. Eastern time and will be conducted virtually. Viking focuses on therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809 for non-alcoholic steatohepatitis (NASH) and VK2735 for various metabolic disorders. The company holds exclusive rights to five therapeutic programs developed from licensed small molecules.
Viking Therapeutics (NASDAQ: VKTX) will announce its fourth quarter and year-end 2022 financial results on February 8, 2023, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. The company focuses on developing therapies for metabolic and endocrine disorders and is currently running clinical trials for its compounds VK2809, VK2735, and VK0214. VK2809 is in a Phase 2b study for treating NASH and fibrosis, showing promising results in earlier trials. Interested parties can participate in the call by dialing specified numbers or can access the webcast on Viking's website.
Viking Therapeutics (NASDAQ: VKTX) announced the completion of patient enrollment in its Phase 2b clinical trial for VK2809, a novel treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). This double-blind, placebo-controlled trial targets a primary endpoint evaluating liver fat content changes at 12 weeks. The study represents a significant advancement in developing therapies for NASH. Viking previously achieved promising results in a Phase 2a trial, demonstrating reductions in liver fat and plasma lipids. Data for the primary endpoint is expected in the first half of 2023.
Viking Therapeutics, Inc. (VKTX) announced that CEO Brian Lian, Ph.D., will present at the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. The presentation is scheduled for 3:35 p.m. Eastern on November 15, and will include a live webcast available on their website. Viking focuses on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for non-alcoholic steatohepatitis and VK2735 for various metabolic disorders.
Viking Therapeutics (VKTX) announced its Q3 2022 financial results, reporting a net loss of $15.8 million, or $0.21 per share, compared to $13.2 million, or $0.17 per share, in Q3 2021. The company ended the quarter with $155 million in cash, supporting ongoing clinical trials for VK2809, VK2735, and VK0214, with data expected in 2023. The Phase 2b VOYAGE study for VK2809 is on track for Q4 2022 enrollment completion. Increased R&D and G&A expenses were noted, affecting the overall financial performance.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
